Hikma stock gets a new CFO as Jefferies keeps Buy rating

Published on 09/28/2026 at 11:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hikma stock was trading at GBp 1,602.00 on September 28, 2026, while Jefferies kept its GBp 2,025.00 target. Branded revenue grew 15 percent in H1 2026.

Fotorealistische sterile Pharma-Produktionslinie mit Injektionsfläschchen und Edelstahlanlagen — Hikma Pharmaceuticals PLC GB00B128J450 zeigt moderne Injektions-Produktionslinie in sterilem Pharmawerk mit Edelstahlanlagen, Illustration mit AI erstellt.

Hikma stock (ISIN GB00B128J450) was trading at GBp 1,602.00 on the London Stock Exchange on September 28, 2026, at 9:59 a.m. BST, up 0.75 percent from the prior close. The latest company catalyst is a planned finance leadership change that puts execution and capital discipline back on the agenda.

Hikma names its next CFO

According to Hikma on September 24, 2026, Rebecca Hall will join as chief financial officer and executive director in Q1 2027. She is moving from ViiV Healthcare, where she served as senior vice president and CFO, while Khalid Nabilsi is scheduled to leave Hikma's board on December 31, 2026.

The appointment gives Hikma a finance chief with pharmaceutical, supply-chain and business-development experience. Acting CFO Areb Kurdi will continue in the role until Hall joins, creating a defined transition period for the group.

Branded revenue grows 15 percent

Hikma's investor-relations materials state that the company released interim results for the six months ended June 30, 2026, on August 6, 2026. In those results, the Branded segment increased revenue by 15 percent, and management reiterated its full-year 2026 guidance, according to Hikma.

That segment comparison matters because it shows where growth is strongest inside a diversified portfolio spanning Injectables, Branded and Hikma Rx. The leadership handover therefore arrives alongside a measurable operating trend rather than a standalone board announcement.

Jefferies keeps GBp 2,025 target

As MarketBeat reported on September 25, 2026, Jefferies reaffirmed a Buy rating and set a GBp 2,025.00 price target. The target stands GBp 423.00 above the September 28 intraday price of GBp 1,602.00, giving investors a clear valuation reference without changing the company's published guidance.

A broader analyst snapshot listed six Buy ratings and a consensus target of GBp 2,085.83 as of September 26, 2026, according to PriceTargets. The gap between the current quote and those targets leaves the market focused on delivery from the Branded and Injectables businesses.

Hikma stock stays below its yearly high

Hikma stock traded between GBp 1,593.00 and GBp 1,606.00 during the September 28 session. Its 52-week range is GBp 1,187.00 to GBp 1,865.00, while market capitalization stood at GBP 3.3 billion and volume reached 17,425 shares.